Prothena Corporation plc (PRTA)
NASDAQ: PRTA · IEX Real-Time Price · USD
23.58
-0.03 (-0.13%)
At close: Jul 19, 2024, 4:00 PM
23.50
-0.08 (-0.34%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Prothena Corporation Revenue
Prothena Corporation had revenue of $89.25M in the twelve months ending March 31, 2024, with 62.51% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $50.00K. In the year 2023, Prothena Corporation had annual revenue of $91.37M with 69.50% growth.
Revenue (ttm)
$89.25M
Revenue Growth
+62.51%
P/S Ratio
14.21
Revenue / Employee
$515,902
Employees
173
Market Cap
1.27B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
Dec 31, 2019 | 814.00K | -141.00K | -14.76% |
Dec 31, 2018 | 955.00K | -26.56M | -96.53% |
Dec 31, 2017 | 27.52M | 26.46M | 2,508.44% |
Dec 31, 2016 | 1.06M | -552.00K | -34.35% |
Dec 31, 2015 | 1.61M | -49.25M | -96.84% |
Dec 31, 2014 | 50.85M | 50.18M | 7,422.78% |
Dec 31, 2013 | 676.00K | -1.98M | -74.57% |
Dec 31, 2012 | 2.66M | 2.15M | 424.26% |
Dec 31, 2011 | 507.00K | -736.00K | -59.21% |
Dec 31, 2010 | 1.24M | - | - |
Dec 31, 2009 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Omnicell | 1.10B |
AtriCure | 414.60M |
Arcus Biosciences | 237.00M |
Xencor | 162.18M |
Ardelyx | 159.11M |
Establishment Labs Holdings | 155.79M |
Gyre Therapeutics | 140.62M |
Immatics | 80.95M |
PRTA News
- 7 weeks ago - Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration - Business Wire
- 2 months ago - Prothena Reports First Quarter 2024 Financial Results and Business Highlights - Business Wire
- 2 months ago - Prothena to Report First Quarter 2024 Financial Results on May 8 - Business Wire
- 3 months ago - Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma - Business Wire
- 4 months ago - Prothena to Participate in Upcoming Healthcare Conferences - Business Wire
- 4 months ago - Prothena Appoints David Ford to Newly Created Chief People Officer Position - Business Wire
- 5 months ago - Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate - Business Wire
- 5 months ago - Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights - Business Wire